A pharmaceutical company with marketed therapeutics in several respiratory disorders wanted to supplement its internal pipeline with external innovation. The company had already searched for potential partners in its home territory, but had not identified any clinical-stage assets in their indications of interest. They also did not have the capacity to continue their search international markets so engaged Alacrita to identify other potential partners and assets, with a particular focus in the US and Europe.
Alacrita conducted the following work plan:
Step 1: Using a combination of product pipeline databases, literature and use of our established scouting networks, we generated a list of prospective clinical-stage products in the inflammatory and fibrosis space;
Step 2: After discussions with the originating scientists, Alacrita provided data on each product candidate for review by the clients’ scientific teams, with the result of identifying viable partnerships for co-development or in-licensing; and
Step 3: In parallel, Alacrita searched its network and conference attendee lists to identify companies of interest and make introductions to the client.Back